Review of Guidelines for Use of Immunotherapies and Targeted Therapies in Melanoma

Summary: <p>Melanoma is the most aggressive form of skin cancer, and while it represents less than 10% of all skin cancers it is responsible for more than 75% of all skin cancer-related deaths. And its incidence continues to increase dramatically: data estimates 76,699 new cases of melanoma have been diagnosed and approximately 9,500 patients have died of the disease in the U.S. during 2013.</p> <p>Please join us as Dr. Omid Hamid addresses critical clinical issues surrounding managing this difficult disease.</p> <p>As of September 4, 2014, the FDA approved Pembrolizumab (Keytruda). This drug won FDA approval for treating advanced or unresectable melanoma in patients not responding to other therapies. This interview may include discussion on this drug or drugs in a related drug class. Please note this updated approval while participating in this activity. To learn more visit: <a href="http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm412802.htm">http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm412802.htm</a></p> <p><strong>Resources:</strong></p> <ul> <li>NCCN Guidelines: <a href="http://www.nccn.org/professionals/physician_gls/f_guidelines.asp">www.nccn.org</a> </li> <li>Society for Immunotherapy in Cancer Guidelines: <a href="http://www.sitcancer.org/about-sitc/initiatives/cancer-immunotherapy-guidelines">www.sitcancer.org</a> </li> </ul> <p><strong>Estimated time to complete activity:</strong> 15 minutes<br><img src="/media/images/cmsimages/CME/project_oncology_257.jpg" alt="" width="257" height="53" border="0"></p>